euro-biotechnology-genomics-congress-2018-tracks

11 / 19

Page 32
N o v e m b e r 2 6 - 2 7 , 2 0 1 8 | M a d r i d , S p a i n
&
&
BIOTECHNOLOGY
Euro Congress on
GENOMICS AND MOLECULAR BIOLOGY
International Conference on
CANCER SCIENCE AND THERAPY
Global Congress on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Euro Biotechnology 2018 & Genomics Congress 2018 & Cancer Congress 2018 Journal of RNA and Genomics | ISSN: 2591-7781 | Volume 14
Wassil Nowicky, J RNA Genomics 2018, Volume 14
THE SELECTIVE EFFECT OF ANTI-CANCER
PREPARATION “UKRAINE” (NSC 631570)
Wassil Nowicky
Nowicky Pharma, Austria
It is well known that all cells possess the negative charge and cancer cells
have a much more negative charge than normal cells. This property has
been used for the creation of the anticancer preparation on basis of greater
celandine alkaloids with the positive charge. The experiment has been carried
out on basis of the sum of greater celandine alkaloids as well as on basis of
the pure chelidonine with the aim to under-stand the mechanism of action of
the preparation NSC 631570. Chelidonine is the tertiary alkaloid and due to it
doesn’t have the property to fluoresce. After its transformation into the quar-
tet alkaloid it becomes a proton, accumulate in cancer tumors very fast what
is visible thanks to its autofluorescence. Until now this preparation has been
tested on over 100 cancer cell lines and on 12 normal cell lines and the results
of the studies carried out in more than 120 universities and research centres
(in particular at the National Cancer Institute (the USA)) have shown that the
NSC 631570 killed only cancer cells without having damaged the normal cells
what confirmed its selective effect. In clinical trials it also has proved its anti-
cancer efficacy and caused no noteworthy side effects. The results of in vitro
studies also have shown the direct deletion of cancer cells and its ability to
regenerate the immune system. Such a property is unusual for an anticancer
agent but as it can be seen the NSC 631570 possesses some distinct immune
properties. In several immune target-effector systems NSC 631570 signifi-
cantly amplified the malignotoxic activity of macrophages, lymphocytes and
NK cells, and stimulates dendritic cells maturation in vitro. While the parame-
ters like B-lymphocytes count, immune globulin concentrations, complement
and acute phase proteins did not changed significantly, it can be postulated
NSC 631570 modulates the cellular part of the immune system whereas the
humoral part remains unaffected.
Wassil Nowicky Director of “Nowicky Pharma” and
President of the Ukrainian Anti-Cancer Institute (Vienna,
Austria). Has finished his study at the Radiotechnical
Faculty of the Technical University of Lviv (Ukraine) with
the end of 1955 with graduation to “Diplomingeniueur”
in 1960 which title was nostrificated in Austria in 1975.
Inventor of the anticancer preparation on basis of celan-
dine alkaloids “NSC-631570”. Author of over 300 scientif-
ic articles dedicated to cancer research. Wassil Nowicky
is a real member of the New York Academy of Sciences,
member of the European Union for applied immunolo-
gy and of the American Association for scientific prog-
ress, honorary doctor of the Janka Ku-pala University in
Hrodno, doctor “honoris causa” of the Open international
universi-ty on complex medicine in Colombo, honorary
member of the Austrian Society of a name od Albert Sch-
weizer. He has received the award for merits of National
guild of pharmacists of America. The award of Austrian
Society of sanitary, hygiene and public health services
and others.
BIOGRAPHY